Stelo, the first FDA-cleared over-the-counter glucose biosensor, joins Dexcom’s G7 in integrating this feature. The technology aims to improve meal tracking accuracy and consistency—key for better glucose management.

Dexcom President Jake Leach highlighted the tool’s role in making diabetes care simpler and more intuitive during the recent ADA 2025 Scientific Sessions in Chicago.

Follow MEDWIRE.AI for breakthroughs in diabetes monitoring and digital health.

The Aprevo platform uses AI-driven planning and 3D printing to tailor implants to each patient’s anatomy and alignment needs. Already FDA-cleared for lumbar fusion, Aprevo devices have also received breakthrough designation for both lumbar and cervical applications.

Dr. Osorio, who has prior experience with the lumbar version, said the technology enables spinal alignment not possible with traditional implants. Carlsmed expects to launch the cervical solution in the U.S. in 2026.

The procedure comes shortly after Carlsmed’s IPO, as the company aims to reshape spine surgery with precision implants designed to reduce revision rates and improve long-term outcomes.

Follow MEDWIRE.AI for breakthroughs in AI-driven surgical technologies.

The company’s AI platform, Heartflow One, includes key tools like Roadmap Analysis, FFRCT Analysis, and Plaque Analysis, which have supported management of over 400,000 heart patients globally. Heartflow’s move follows major policy milestones boosting adoption and reimbursement, including expanded Medicare coverage for coronary plaque evaluation tools and a new CPT code set to take effect in 2026.

In November 2024, CMS nearly doubled Medicare reimbursements for CCTA procedures, raising the payment rate from $175 to $357.13, enhancing clinical and economic incentives for Heartflow’s offerings.

Recent data presented at SCCT 2025 show Heartflow’s Plaque Analysis changes patient management by enabling personalized treatment based on plaque burden and risk stratification.

Heartflow nearly went public in 2021 via a merger with Longview Acquisition Corp. II but withdrew due to market conditions. The current IPO filing signals renewed confidence amid a growing market for AI-driven cardiac diagnostics.

Follow MEDWIRE.AI for the latest in cardiovascular AI innovation and market developments.

Presented at SCCT 2025, data from nearly 1,000 patients across 15 U.S. sites show that more than half experienced changes in medical management when Heartflow’s technology was used, surpassing decisions made from coronary CT angiography (CCTA) alone. Patients guided by Plaque Analysis, including the new Plaque Staging tool, saw an average LDL cholesterol reduction of 18.7 mg/dL—translating to a 15% estimated decrease in cardiac event risk.

Unlike traditional risk factors or CCTA, Heartflow’s AI quantifies both calcified and soft plaque types, offering a precise, patient-specific risk profile. The Plaque Staging system classifies plaque burden into four risk categories validated by the FISH&CHIPS study, which found up to a fivefold increase in cardiovascular events for higher-risk groups.

“Heartflow Plaque Analysis empowers personalized care, enabling earlier intervention that can alter disease progression,” said Campbell Rogers, MD, Heartflow’s chief medical officer.

Experts view AI-based soft plaque quantification as a potential paradigm shift in coronary disease screening and prevention, supporting earlier detection and more tailored long-term management.

Follow MEDWIRE.AI for the latest in AI-driven cardiovascular diagnostics and innovations.

By managing vendor connections within a single platform, Philips aims to reduce IT overhead and operational costs associated with handling multiple AI tool interfaces. The marketplace offers direct access to a broad portfolio of AI algorithms at the point of care.

Anumana is the first partner to adopt the marketplace, offering its FDA-cleared ECG-AI low ejection fraction (LEF) algorithm. This collaboration exemplifies Philips’ commitment to an open ecosystem, fostering innovation and early heart disease detection.

“Philips ECG AI Marketplace builds a more connected and flexible approach to cardiac care innovation,” said Stefano Folli, Philips business leader for Ambulatory Monitoring and Diagnostics.

Follow MEDWIRE.AI for the latest in cardiac AI technology.

The new Swoop system features enhanced image quality and faster acquisition times, driven by a high signal-to-noise ratio combined with Optive AI’s capabilities. Designed with patient and user experience in mind, it aims to serve a wide patient population.

Swoop remains the only FDA-cleared ultra-low-field portable brain MRI, with Hyperfine focused on expanding access and advancing imaging technology through AI and machine learning.

“This milestone reflects our seamless execution and growing customer interest,” said Hyperfine CEO Maria Sainz. “We anticipate strong growth in the second half of 2025 and beyond.”

Follow MEDWIRE.AI for latest AI innovations in neuroimaging.

The model uses a single echocardiography videoclip to identify all major amyloidosis types, distinguishing them from similar cardiac conditions. Cardiac amyloidosis causes heart stiffening due to abnormal amyloid protein deposits, often leading to heart failure and frequently missed due to symptom overlap with other diseases.

Early diagnosis is critical as emerging drug therapies can slow disease progression but not reverse existing damage. The AI integrates with echo PACS systems, facilitating widespread use in echo labs.

Dr. Patricia Pellikka of Mayo Clinic, a key investigator, highlighted the model’s robust performance across amyloid phenotypes (AL, wtATTR, hATTR). This work follows their FDA-cleared AI model for detecting heart failure with preserved ejection fraction.

Follow MEDWIRE.AI for advances in AI-driven cardiovascular diagnostics.

Since 2021, Optibrium has seen rapid adoption of its computational platforms by over 160 pharmaceutical and biotech organizations worldwide. The company aims to further improve drug discovery speed and efficiency amid a market expected to reach $13 billion by 2034.

Peter Ralph of Kester Capital and Shawbrook’s Jack Longden highlighted Optibrium’s growth and innovation, underscoring the new capital’s role in sustaining the company’s technological leadership.

Follow MEDWIRE.AI for updates on AI and computational drug discovery.

Martin Stumpe will become chief technology and AI officer, effective October 1, 2025. Stumpe, who joined last year as chief data and AI officer, reports directly to CEO Rainer Blair. He brings experience from Tempus, Google’s Cancer Pathology project, and NASA’s Kepler team.

Greg Milosevich is named executive vice president overseeing Life Sciences, effective July 1, 2025. Milosevich has led Danaher’s Life Sciences Innovations Group since 2021 and has held increasing responsibilities since joining via Molecular Devices in 2010.

“These appointments mark a pivotal step in accelerating Danaher’s integration of AI and driving Life Sciences growth,” said Blair.

Follow MEDWIRE.AI for leadership and innovation updates in MedTech.

The fund targets support for AI model development, data engineering, and governance, emphasizing responsible data use and collaboration. Through the QuickFire Challenge program, Johnson & Johnson will offer grants up to $100,000 and expert mentorship to selected researchers, startups, and companies—both academic and commercial.

Building on a prior partnership with Nvidia in surgical robotics, this initiative aims to enhance surgical video data science by creating annotated datasets and establishing governance frameworks for AI models in the operating room.

“Open innovation and open minds breed the best solutions in service of patients,” said Hani Abouhalka, chair of Surgery at Johnson & Johnson MedTech. The fund seeks to deliver AI solutions that improve surgical outcomes worldwide by leveraging the digital ecosystem of Johnson & Johnson MedTech and its partners.

Follow MEDWIRE.AI for insights on AI innovations in surgical technology.